Cytochrome P450: Another Player in the Myocardial Infarction Game?

Advances in Clinical Chemistry

Volumn 43, Issue , 2007, Pages 229-280

  Sunder Plassmann, Raute ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

ENZYMOLOGY; GENE EXPRESSION REGULATION; HEART INFARCTION; HUMAN; METABOLISM; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MYOCARDIAL INFARCTION;

EID: 33845630317     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(06)43008-0     Document Type: Review

References (472)

1. Hamm C., Bertrand M., and Braunwald E. Acute coronary syndrome without ST elevation: Implementation of new guidelines. Lancet 358 (2001) 1533-1538
2. Boersma E., Mercado N., Poldermans D., Gardien M., Vos J., and Simoons M. Acute myocardial infarction. Lancet 361 (2003) 847-858
3. Nabel E. Cardiovascular disease. N Engl J Med 349 (2003) 60-72
4. Kesteloot H. Evolution of all-cause mortality rates in the United States of America, anno 1900-1999. Acta Cardiol 57 (2002) 1-4
5. Sans S., Kesteloot H., and Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 18 (1997) 1231-1248
6. Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., Tolonen H., Ruokokoski E., and Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353 (1999) 1547-1557
7. Tunstall-Pedoe H., Vanuzzo D., Hobbs M., Mahonen M., Cepaitis Z., Kuulasmaa K., et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 355 (2000) 688-700
8. Reitsma J., Dalstra J., Bonsel G., van der Meulen J., Koster R., Gunning-Schepers L., et al. Cardiovascular disease in the Netherlands, 1975 to 1995: Decline in mortality, but increasing numbers of patients with chronic conditions. Heart 82 (1999) 52-56
9. Fuster V., Badimon L., Badimon J., and Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326 (1992) 310-318
10. Fuster V., Badimon L., Badimon J., and Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 (1992) 242-250
11. Rauch U., Osende J., Fuster V., Badimon J., Fayad Z., and Chesebro J. Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences. Ann Intern Med 134 (2001) 224-238
12. Rose G. Strategies of prevention: The individual and the population. In: Marmot M., and Elliot P. (Eds). Coronary Heart Disease Epidemiology: From Aetiology to Public Health (1992), Oxford University Press, Oxford 311-324
13. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., and Pyorala K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 140 (1998) 199-270
14. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364 (2004) 937-952
15. O'Callaghan P., Fitzgerald A., Fogarty J., Gaffney P., Hanbidge M., Boran G., et al. New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers. Eur J Cardiovasc Prev Rehabil 12 (2005) 542-547
16. Andreotti F., Porto I., Crea F., and Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: Review of population association studies. Heart 87 (2002) 107-112
17. Hennekens C. Increasing burden of cardiovascular disease: Current knowledge and future directions for research on risk factors. Circulation 97 (1998) 1095-1102
18. Gross G., Falck J., Gross E., Isbell M., Moore J., and Nithipatikom K. Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res 68 (2005) 18-25
19. Spiecker M., Darius H., Hankeln T., Soufi M., Sattler A., Schaefer J., et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110 (2004) 2132-2136
20. Spiecker M., and Liao J. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433 (2005) 413-420
21. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
22. Freemantle N., Cleland J., Young P., Mason J., and Harrison J. beta Blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 318 (1999) 1730-1737
23. Latini R., Tognoni G., Maggioni A., Baigent C., Braunwald E., Chen Z., et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 35 (2000) 1801-1807
24. Schwartz G., Olsson A., Ezekowitz M., Ganz P., Oliver M., Waters D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA 285 (2001) 1711-1718
25. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 357 (2001) 995-1001
26. Eagle K., Kline-Rogers E., Goodman S., Gurfinkel E., Avezum A., Flather M., et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am J Med 117 (2004) 73-81
27. Harder S., Thurmann P., Thierolf C., and Klepzig H. Prescription of cardiovascular drugs in outpatient care: A survey of outpatients in a German university hospital. Int J Clin Pharmacol Ther 36 (1998) 195-201
28. Roe C., Motheral B., Teitelbaum F., and Rich M. Compliance with and dosing of angiotensin-converting-enzyme inhibitors before and after hospitalization. Am J Health Syst Pharm 57 (2000) 139-145
29. Coon M., Ding X., Pernecky S., and Vaz A. Cytochrome P450: Progress and predictions. FASEB J 6 (1992) 669-673
30. Gottlieb R. Cytochrome P450: Major player in reperfusion injury. Arch Biochem Biophys 420 (2003) 262-267
31. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: Properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 89-104
32. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res 89 (2001) 753-762
33. Oyekan A., McAward K., Conetta J., Rosenfeld L., and McGiff J. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am J Physiol 276 (1999) R766-R775
34. Scarborough P., Ma J., Qu W., and Zeldin D. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31 (1999) 205-234
35. Zhu D., Zhang C., Medhora M., and Jacobs E. CYP4A mRNA, protein, and product in rat lungs: Novel localization in vascular endothelium. J Appl Physiol 93 (2002) 330-337
36. Thum T., and Borlak J. Gene expression in distinct regions of the heart. Lancet 355 (2000) 979-983
37. Capdevila J., Falck J., and Harris R. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41 (2000) 163-181
38. Ivnitski I., Elmaoued R., and Walker M. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inhibition of coronary development is preceded by a decrease in myocyte proliferation and an increase in cardiac apoptosis. Teratology 64 (2001) 201-212
39. Capdevila J., Chacos N., Werringloer J., Prough R., and Estabrook R. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc Natl Acad Sci USA 78 (1981) 5362-5366
40. Carroll M., and McGiff J. Renal cytochrome P450-dependent eicosanoids. Adv Exp Med Biol 407 (1997) 255-260
41. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D., Fleming I., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401 (1999) 493-497
42. Rastaldo R., Paolocci N., Chiribiri A., Penna C., Gattullo D., and Pagliaro P. Cytochrome P-450 metabolite of arachidonic acid mediates bradykinin-induced negative inotropic effect. Am J Physiol Heart Circ Physiol 280 (2001) H2823-H2832
43. Roman R., Maier K., Sun C., Harder D., and Alonso-Galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 27 (2000) 855-865
44. Wu S., Moomaw C., Tomer K., Falck J., and Zeldin D. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271 (1996) 3460-3468
45. Tang C., Lin J., and Lu A. Metabolism-based drug-drug interactions: What determines individual variability in cytochrome P450 induction?. Drug Metab Dispos 33 (2005) 603-613
46. Ingelman-Sundberg M., Oscarson M., and McLellan R. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 20 (1999) 342-349
47. Lin J., and Lu A. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35 (1998) 361-390
48. Lin J., and Lu A. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41 (2001) 535-567
49. Meyer U., and Zanger U. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37 (1997) 269-296
50. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
51. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482 (2001) 11-19
52. Cao H., and Hegele R. Human aryl hydrocarbon receptor nuclear translocator gene (ARNT) D/N511 polymorphism. J Hum Genet 45 (2000) 92-93
53. Cheng P., and Morgan E. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2 (2001) 165-183
54. Conney A. Induction of drug-metabolizing enzymes: A path to the discovery of multiple cytochromes P450. Annu Rev Pharmacol Toxicol 43 (2003) 1-30
55. Hustert E., Zibat A., Presecan-Siedel E., Eiselt R., Mueller R., Fuss C., et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29 (2001) 1454-1459
56. Lin P., Hu S., and Chang T. Correlation between gene expression of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P450 1A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes. Toxicol Sci 71 (2003) 20-26
57. Smart J., and Daly A. Variation in induced CYP1A1 levels: Relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 10 (2000) 11-24
58. Zhang J., Kuehl P., Green E., Touchman J., Watkins P., Daly A., et al. The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11 (2001) 555-572
59. Weinshilboum R. Inheritance and drug response. N Engl J Med 348 (2003) 529-537
60. Conney A., Pantuck E., Hsiao K., Kuntzman R., Alvares A., and Kappas A. Regulation of drug metabolism in man by environmental chemicals and diet. Fed Proc 36 (1977) 1647-1652
61. Handschin C., and Meyer U. Induction of drug metabolism: The role of nuclear receptors. Pharmacol Rev 55 (2003) 649-673
62. Bradford L. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3 (2002) 229-243
63. Krishna D., and Shekar M. Cytochrome P450 3A: Genetic polymorphisms and inter-ethnic differences. Methods Find Exp Clin Pharmacol 27 (2005) 559-567
64. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35 (2003) 99-106
65. Solus J., Arietta B., Harris J., Sexton D., Steward J., McMunn C., et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5 (2004) 895-931
66. Xie H., Kim R., Wood A., and Stein C. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41 (2001) 815-850
67. Ingelman-Sundberg M., and Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: Implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 360 (2005) 1563-1570
68. Meyer U., Zanger U., Skoda R., and Grant D. Genetic polymorphisms of drug-metabolizing enzymes: Molecular mechanisms. Psychopharmacol Ser 7 (1989) 141-147
69. Nagata K., and Yamazoe Y. Genetic polymorphism of human cytochrome p450 involved in drug metabolism. Drug Metab Pharmacokinet 17 (2002) 167-189
70. Pelkonen O., Rautio A., Raunio H., and Pasanen M. CYP2A6: A human coumarin 7-hydroxylase. Toxicology 144 (2000) 139-147
71. Koskela S., Hakkola J., Hukkanen J., Pelkonen O., Sorri M., Saranen A., et al. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 57 (1999) 1407-1413
72. Castell J., Donato M., and Gomez-Lechon M. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. Exp Toxicol Pathol 57 Suppl. 1 (2005) 189-204
73. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29 (2001) 91-95
74. Wang H., Hao B., Zhou G., He F., Tan W., Miao X., et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63 (2003) 8057-8061
75. Nunoya K., Yokoi T., Kamataki T., Kimura K., Kainuma T., Satoh K., et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 289 (1999) 437-442
76. Oscarson M., McLellan R., Ingelman-Sundberg M., GullstÈn H., Raunio H., Pelkonen O., et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448 (1999) 105-110
77. Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E., et al. Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58 (2000) 747-755
78. Oscarson M., McLellan R., Asp V., Ledesma M., Bernal Ruiz M., Sinues B., et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 20 (2002) 275-283
79. Oscarson M., McLellan R., Gullsten H., Yue Q., Lang M., Bernal M., et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448 (1999) 105-110
80. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., and Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: Impairment of its promoter activity. Biochem Biophys Res Commun 284 (2001) 455-460
81. Haberl M., Anwald B., Klein K., Weil R., Fuss C., Gepdiremen A., et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 15 (2005) 609-624
82. Nakajima M., Yamagishi S., Yamamoto H., Yamamoto T., Kuroiwa Y., and Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 67 (2000) 57-69
83. Ariyoshi N., Takahashi Y., Miyamoto M., Umetsu Y., Daigo S., Tateishi T., et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics 10 (2000) 687-693
84. Oscarson M., McLellan R., Ingelman-Sundberg M., GullstÈn H., Rautio A., Raunio H., et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism. FEBS Lett 460 (1999) 321-327
85. Raunio H., Rautio A., GullstÈn H., and Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52 (2001) 357-363
86. Nakajima M., Kwon J., Tanaka N., Zenta T., Yamamoto Y., Yamamoto H., et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 69 (2001) 72-78
87. Ujjin P., Satarug S., Vanavanitkun Y., Daigo S., Ariyoshi N., Yamazaki H., et al. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. Pharmacogenetics 12 (2002) 241-249
88. Yoshida R., Nakajima M., Watanabe Y., Kwon J., and Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54 (2002) 511-517
89. Wang J., Pitarque M., and Ingelman-Sundberg M. 3′-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun 340 (2006) 491-497
90. Gambier N., Batt A., Marie B., Pfister M., Siest G., and Visvikis-Siest S. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J 5 (2005) 271-275
91. Gervot L., Rochat B., Gautier J., Bohnenstengel F., Kroemer H., de Berardinis V., et al. Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 9 (1999) 295-306
92. Roy P., Yu L., Crespi C., and Waxman D. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27 (1999) 655-666
93. Court M., Duan S., Hesse L., Venkatakrishnan K., and Greenblatt D. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94 (2001) 110-119
94. Faucette S., Hawke R., Lecluyse E., Shord S., Yan B., Laethem R., et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28 (2000) 1222-1230
95. Svensson U., and Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 48 (1999) 528-535
96. Ward B., Gorski J., Jones D., Hall S., Flockhart D., and Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306 (2003) 287-300
97. Code E., Crespi C., Penman B., Gonzalez F., Chang T., and Waxman D. Human cytochrome P450 2B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25 (1997) 985-993
98. Jinno H., Tanaka-Kagawa T., Ohno A., Makino Y., Matsushima E., Hanioka N., et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31 (2003) 398-403
99. Kirchheiner J., Klein C., Meineke I., Sasse J., Zanger U., Murdter T., et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13 (2003) 619-626
100. Lang T., Klein K., Fischer J., Nussler A., Neuhaus P., Hofmann U., et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11 (2001) 399-415
101. Lang T., Klein K., Richter T., Zibat A., Kerb R., Eichelbaum M., et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: Demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311 (2004) 34-43
102. Zukunft J., Lang T., Richter T., Hirsch-Ernst K., Nussler A., Klein K., et al. A natural CYP2B6 TATA box polymorphism (-82T→ C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 67 (2005) 1772-1782
103. Hesse L., He P., Krishnaswamy S., Hao Q., Hogan K., von Moltke L., et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14 (2004) 225-238
104. Tsuchiya K., Gatanaga H., Tachikawa N., Teruya K., Kikuchi Y., Yoshino M., et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319 (2004) 1322-1326
105. Xie H., Yasar U., Lundgren S., Griskevicius L., Terelius Y., Hassan M., et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3 (2003) 53-61
106. Ariyoshi N., Miyazaki M., Toide K., Sawamura Y., and Kamataki T. A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 281 (2001) 1256-1260
107. Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M., et al. Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307 (2003) 906-922
108. Goodwin B., Moore L., Stoltz C., McKee D., and Kliewer S. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60 (2001) 427-431
109. Wang H., Faucette S., Sueyoshi T., Moore R., Ferguson S., Negishi M., et al. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278 (2003) 14146-14152
110. Capdevila J., and Falck J. Biochemical and molecular characteristics of the cytochrome P450 arachidonic acid monooxygenase. Prostaglandins Other Lipid Mediat 62 (2000) 271-292
111. Hunter A., Bai N., Laher I., and Granville D. Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction. Vascul Pharmacol 43 (2005) 213-219
112. Fichtlscherer S., Dimmeler S., Breuer S., Zeiher A., Busse R., and Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 109 (2004) 178-183
113. Funk M., Endler G., Freitag R., Mannhalter C., Sunder-Plassmann R., Wojta J., et al. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem 50 (2004) 2395-2398
114. Yasar U., Eliasson E., Lundgren S., Rane A., Bennet A., De Faire U., et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13 (2003) 715-720
115. Kirchheiner J., and Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77 (2005) 1-16
116. Dai D., Zeldin D., Blaisdell J., Chanas B., Coulter S., Ghanayem B., et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 (2001) 597-607
117. Lee C. CYP2C9 genotype as a predictor of drug disposition in humans. Methods Find Exp Clin Pharmacol 26 (2004) 463-472
118. Lee C., Goldstein J., and Pieper J. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 12 (2002) 251-263
119. King B., Khan T., Aithal G., Kamali F., and Daly A. Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism. Pharmacogenetics 14 (2004) 813-822
120. Shintani M., Ieiri I., Inoue K., Mamiya K., Ninomiya H., Tashiro N., et al. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: In vitro and in vivo studies. Clin Pharmacol Ther 70 (2001) 175-182
121. Aithal G., Day C., Kesteven P., and Daly A. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
122. Higashi M., Veenstra D., Kondo L., Wittkowsky A., Srinouanprachanh S., Farin F., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
123. Tabrizi A., Zehnbauer B., Borecki I., McGrath S., Buchman T., and Freeman B. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 194 (2002) 267-273
124. Zanger U., Raimundo S., and Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 23-37
125. Gonzalez F., Skoda R., Kimura S., Umeno M., Zanger U., Nebert D., et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331 (1988) 442-446
126. Gough A., Miles J., Spurr N., Moss J., Gaedigk A., Eichelbaum M., et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347 (1990) 773-776
127. Heim M., and Meyer U. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14 (1992) 49-58
128. Johansson I., Lundqvist E., Bertilsson L., Dahl M., Sjoqvist F., and Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90 (1993) 11825-11829
129. Kimura S., Umeno M., Skoda R., Meyer U., and Gonzalez F. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45 (1989) 889-904
130. Marez D., Legrand M., Sabbagh N., Lo Guidice J., Spire C., Broly F., et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7 (1997) 193-202
131. Raimundo S., Fischer J., Eichelbaum M., Griese E., Schwab M., and Zanger U. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10 (2000) 577-581
132. Soyama A., Kubo T., Miyajima A., Saito Y., Shiseki K., Komamura K., et al. Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene. Drug Metab Pharmacokinet 19 (2004) 313-319
133. Zanger U., Fischer J., Raimundo S., Stuven T., Evert B., Schwab M., et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11 (2001) 573-585
134. Zanger U., Vilbois F., Hardwick J., and Meyer U. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27 (1988) 5447-5454
135. Raimundo S., Toscano C., Klein K., Fischer J., Griese E., Eichelbaum M., et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76 (2004) 128-138
136. Denson J., Wu Y., Yang W., and Zhang J. Inter-individual variation of several cytochrome P450 2D6 splice variants in human liver. Biochem Biophys Res Commun 330 (2005) 498-504
137. Pai H., Kommaddi R., Chinta S., Mori T., Boyd M., and Ravindranath V. A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P450 2D7 that demethylates codeine to morphine. J Biol Chem 279 (2004) 27383-27389
138. Zhang F., Deng H., Kemp R., Singh H., Gopal V., Falck J., et al. Decreased levels of cytochrome P450 2E1-derived eicosanoids sensitize renal arteries to constrictor agonists in spontaneously hypertensive rats. Hypertension 45 (2005) 103-108
139. Borlak J., Walles M., Levsen K., and Thum T. Verapamil: Metabolism in cultures of primary human coronary arterial endothelial cells. Drug Metab Dispos 31 (2003) 888-891
140. Gonzalez F. Role of cytochromes P450 in chemical toxicity and oxidative stress: Studies with CYP2E1. Mutat Res 569 (2005) 101-110
141. McCarver D., Byun R., Hines R., Hichme M., and Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 152 (1998) 276-281
142. Fairbrother K., Grove J., de Waziers I., Steimel D., Day C., Crespi C., et al. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 8 (1998) 543-552
143. Hu Y., Hakkola J., Oscarson M., and Ingelman-Sundberg M. Structural and functional characterization of the 5′-flanking region of the rat and human cytochrome P450 2E1 genes: Identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 263 (1999) 286-293
144. Bauer M., Herbarth O., Aust G., and Graebsch C. Molecular cloning and expression of novel alternatively spliced cytochrome P450 2E1 mRNAs in humans. Mol Cell Biochem 280 (2005) 201-207
145. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
146. Oltman C., Weintraub N., VanRollins M., and Dellsperger K. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 83 (1998) 932-939
147. Finta C., and Zaphiropoulos P. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260 (2000) 13-23
148. Hustert E., Haberl M., Burk O., Wolbold R., He Y., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11 (2001) 773-779
149. Koch I., Weil R., Wolbold R., Brockmoller J., Hustert E., Burk O., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30 (2002) 1108-1114
150. Daly A. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45 (2006) 13-31
151. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
152. Lacroix D., Sonnier M., Moncion A., Cheron G., and Cresteil T. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247 (1997) 625-634
153. Schuetz J., Beach D., and Guzelian P. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4 (1994) 11-20
154. Burk O., and Wojnowski L. Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 105-124
155. Dai D., Tang J., Rose R., Hodgson E., Bienstock R., Mohrenweiser H., et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299 (2001) 825-831
156. Eichelbaum M., and Burk O. CYP3A genetics in drug metabolism. Nat Med 7 (2001) 285-287
157. Lamba J., Lin Y., Schuetz E., and Thummel K. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54 (2002) 1271-1294
158. Westlind A., Lofberg L., Tindberg N., Andersson T., and Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259 (1999) 201-205
159. Chang T., Bandiera S., and Chen J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: Interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31 (2003) 7-10
160. Pascussi J., Drocourt L., Gerbal-Chaloin S., Fabre J., Maurel P., and Vilarem M. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268 (2001) 6346-6358
161. Matsumura K., Saito T., Takahashi Y., Ozeki T., Kiyotani K., Fujieda M., et al. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol 65 (2004) 326-334
162. Anttila S., Hukkanen J., Hakkola J., Stjernvall T., Beaune P., Edwards R., et al. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 16 (1997) 242-249
163. Boobis A., Edwards R., Adams D., and Davies D. Dissecting the function of cytochrome P450. Br J Clin Pharmacol 42 (1996) 81-89
164. Jounaidi Y., Hyrailles V., Gervot L., and Maurel P. Detection of CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein?. Biochem Biophys Res Commun 221 (1996) 466-470
165. Givens R., Lin Y., Dowling A., Thummel K., Lamba J., Schuetz E., et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 95 (2003) 1297-1300
166. Xie H., Wood A., Kim R., Stein C., and Wilkinson G. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5 (2004) 243-272
167. Fromm M., Schmidt B., Pahl A., Jacobi J., and Schmieder R. CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics 15 (2005) 737-741
168. Kivisto K., Niemi M., Schaeffeler E., Pitkala K., Tilvis R., Fromm M., et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: Data from the DEBATE Study. Am J Pharmacogenomics 5 (2005) 191-195
169. Kreutz R., Zuurman M., Kain S., Bolbrinker J., de Jong P., and Navis G. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics 15 (2005) 831-837
170. Ho H., Pinto A., Hall S., Flockhart D., Li L., Skaar T., et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 45 (2005) 294-298
171. Kimura S., Hanioka N., Matsunaga E., and Gonzalez F. The rat clofibrate-inducible CYP4A gene subfamily. I. Complete intron and exon sequence of the CYP4A1 and CYP4A2 genes, unique exon organization, and identification of a conserved 19-bp upstream element. DNA 8 (1989) 503-516
172. Kimura S., Hardwick J., Kozak C., and Gonzalez F. The rat clofibrate-inducible CYP4A subfamily. II. cDNA sequence of IVA3, mapping of the Cyp4a locus to mouse chromosome 4, and coordinate and tissue-specific regulation of the CYP4A genes. DNA 8 (1989) 517-525
173. Powell P., Wolf I., Jin R., and Lasker J. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: Involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 285 (1998) 1327-1336
174. Simpson A. The cytochrome P450 4 (CYP4) family. Gen Pharmacol 28 (1997) 351-359
175. Nelson D., Koymans L., Kamataki T., Stegeman J., Feyereisen R., Waxman D., et al. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
176. Hoch U., Zhang Z., Kroetz D., and Ortiz de Montellano P. Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omega-hydroxylases. Arch Biochem Biophys 373 (2000) 63-71
177. Imaoka S., Ogawa H., Kimura S., and Gonzalez F. Complete cDNA sequence and cDNA-directed expression of CYP4A11, a fatty acid omega-hydroxylase expressed in human kidney. DNA Cell Biol 12 (1993) 893-899
178. Roman R. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82 (2002) 131-185
179. Gainer J., Bellamine A., Dawson E., Womble K., Grant S., Wang Y., et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111 (2005) 63-69
180. Mayer B., Lieb W., Gotz A., Konig I., Aherrahrou Z., Thiemig A., et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 46 (2005) 766-771
181. Hiratsuka M., Nozawa H., Konno Y., Saito T., Konno S., and Mizugaki M. Human CYP4B1 gene in the Japanese population analyzed by denaturing HPLC. Drug Metab Pharmacokinet 19 (2004) 114-119
182. Lo-Guidice J., Allorge D., Cauffiez C., Chevalier D., Lafitte J., Lhermitte M., et al. Genetic polymorphism of the human cytochrome P450 CYP4B1: Evidence for a non-functional allelic variant. Pharmacogenetics 12 (2002) 367-374
183. Kikuta Y., Kusunose E., and Kusunose M. Characterization of human liver leukotriene B(4) omega-hydroxylase P450 (CYP4F2). J Biochem (Tokyo) 127 (2000) 1047-1052
184. Kikuta Y., Kusunose E., and Kusunose M. Prostaglandin and leukotriene omega-hydroxylases. Prostaglandins Other Lipid Mediat 68-69 (2002) 345-362
185. Bylund J., Harder A., Maier K., Roman R., and Harder D. Leukotriene B4 omega-side chain hydroxylation by CYP4F5 and CYP4F6. Arch Biochem Biophys 412 (2003) 34-41
186. Bylund J., Hidestrand M., Ingelman-Sundberg M., and Oliw E. Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. J Biol Chem 275 (2000) 21844-21849
187. Bylund J., Bylund M., and Oliw E. cDna cloning and expression of CYP4F12, a novel human cytochrome P450. Biochem Biophys Res Commun 280 (2001) 892-897
188. Hashizume T., Imaoka S., Mise M., Terauchi Y., Fujii T., Miyazaki H., et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300 (2002) 298-304
189. Christmas P., Ursino S., Fox J., and Soberman R. Expression of the CYP4F3 gene. Tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega-hydroxylase. J Biol Chem 274 (1999) 21191-21199
190. Christmas P., Jones J., Patten C., Rock D., Zheng Y., Cheng S., et al. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem 276 (2001) 38166-38172
191. Riley R. The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discov Devel 4 (2001) 45-54
192. Whitlock Jr. J. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39 (1999) 103-125
193. Lefebvre P., Chinetti G., Fruchart J., and Staels B. Sorting out the roles of PPARalpha in energy metabolism and vascular homeostasis. J Clin Invest 116 (2006) 571-580
194. Hayashi S., Watanabe J., Nakachi K., Eguchi H., Gotoh O., and Kawajiri K. Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis 15 (1994) 801-806
195. Lin P., Chang H., Ho W., Wu M., and Su J. Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer 42 (2003) 255-261
196. Okey A., Riddick D., and Harper P. Ah receptor role in TCDD toxicity: Still some mysteries but no myth-a reply to the commentary by Dr. L.W.D. Weber and Dr. B.U. Stahl. Toxicol Lett 75 (1995) 249-254
197. Harper P., Wong J., Lam M., and Okey A. Polymorphisms in the human AH receptor. Chem Biol Interact 141 (2002) 161-187
198. Manchester D., Gordon S., Golas C., Roberts E., and Okey A. Ah receptor in human placenta: Stabilization by molybdate and characterization of binding of 2,3,7, 8-tetrachlorodibenzo-p-dioxin, 3-methylcholanthrene, and benzo(a)pyrene. Cancer Res 47 (1987) 4861-4868
199. Anttila S., Lei X., Elovaara E., Karjalainen A., Sun W., Vainio H., et al. An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. Pharmacogenetics 10 (2000) 741-751
200. Scheel J., Hussong R., Schrenk D., and Schmitz H. Variability of the human aryl hydrocarbon receptor nuclear translocator (ARNT) gene. J Hum Genet 47 (2002) 217-224
201. Watanabe T., Imoto I., Kosugi Y., Fukuda Y., Mimura J., Fujii Y., et al. Human arylhydrocarbon receptor repressor (AHRR) gene: Genomic structure and analysis of polymorphism in endometriosis. J Hum Genet 46 (2001) 342-346
202. Okey A., Boutros P., and Harper P. Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes. Pharmacogenet Genomics 15 (2005) 371-379
203. Okey A., Franc M., Moffat I., Tijet N., Boutros P., Korkalainen M., et al. Toxicological implications of polymorphisms in receptors for xenobiotic chemicals: The case of the aryl hydrocarbon receptor. Toxicol Appl Pharmacol 207 (2005) 43-51
204. Chang T., and Waxman D. Pregnane X receptor-mediated transcription. Methods Enzymol 400 (2005) 588-598
205. Kliewer S., Goodwin B., and Willson T. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr Rev 23 (2002) 687-702
206. Waxman D. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369 (1999) 11-23
207. Lehmann J., McKee D., Watson M., Willson T., Moore J., and Kliewer S. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102 (1998) 1016-1023
208. Schuetz E. Lessons from the CYP3A4 promoter. Mol Pharmacol 65 (2004) 279-281
209. Goodwin B., Redinbo M., and Kliewer S. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 42 (2002) 1-23
210. Sueyoshi T., and Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41 (2001) 123-143
211. Kawana K., Ikuta T., Kobayashi Y., Gotoh O., Takeda K., and Kawajiri K. Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol Pharmacol 63 (2003) 524-531
212. Squires E., Sueyoshi T., and Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 279 (2004) 49307-49314
213. Staudinger J., Liu Y., Madan A., Habeebu S., and Klaassen C. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 29 (2001) 1467-1472
214. Xie W., Radominska-Pandya A., Shi Y., Simon C., Nelson M., Ong E., et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 98 (2001) 3375-3380
215. Koyano S., Kurose K., Saito Y., Ozawa S., Hasegawa R., Komamura K., et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): One variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 32 (2004) 149-154
216. Fukuen S., Fukuda T., Matsuda H., Sumida A., Yamamoto I., Inaba T., et al. Identification of the novel splicing variants for the hPXR in human livers. Biochem Biophys Res Commun 298 (2002) 433-438
217. Gardner-Stephen D., Heydel J., Goyal A., Lu Y., Xie W., Lindblom T., et al. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos 32 (2004) 340-347
218. Lamba V., Yasuda K., Lamba J., Assem M., Davila J., Strom S., et al. PXR (NR1I2): Splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199 (2004) 251-265
219. Kurose K., Koyano S., Ikeda S., Tohkin M., Hasegawa R., and Sawada J. 5′ diversity of human hepatic PXR (NR1I2) transcripts and identification of the major transcription initiation site. Mol Cell Biochem 273 (2005) 79-85
220. Savkur R., Wu Y., Bramlett K., Wang M., Yao S., Perkins D., et al. Alternative splicing within the ligand binding domain of the human constitutive androstane receptor. Mol Genet Metab 80 (2003) 216-226
221. Oesch-Bartlomowicz B., and Oesch F. Cytochrome-P450 phosphorylation as a functional switch. Arch Biochem Biophys 409 (2003) 228-234
222. Oesch-Bartlomowicz B., and Oesch F. Phosphorylation of cytochromes P450: First discovery of a posttranslational modification of a drug-metabolizing enzyme. Biochem Biophys Res Commun 338 (2005) 446-449
223. Pyerin W., Wolf C., Kinzel V., Kubler D., and Oesch F. Phosphorylation of cytochrome-P-450-dependent monooxygenase components. Carcinogenesis 4 (1983) 573-576
224. Bartlomowicz B., Waxman D., Utesch D., Oesch F., and Friedberg T. Phosphorylation of carcinogen metabolizing enzymes: Regulation of the phosphorylation status of the major phenobarbital inducible cytochromes P-450 in hepatocytes. Carcinogenesis 10 (1989) 225-228
225. Eliasson E., Mkrtchian S., and Ingelman-Sundberg M. Hormone- and substrate-regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-activated rapid proteolysis in the endoplasmic reticulum membranes. J Biol Chem 267 (1992) 15765-15769
226. Koch J., and Waxman D. Posttranslational modification of hepatic cytochrome P-450. Phosphorylation of phenobarbital-inducible P-450 forms PB-4 (IIB1) and PB-5 (IIB2) in isolated rat hepatocytes and in vivo. Biochemistry 28 (1989) 3145-3152
227. Oesch-Bartlomowicz B., Richter B., Becker R., Vogel S., Padma P., Hengstler J., et al. cAMP-dependent phosphorylation of CYP2B1 as a functional switch for cyclophosphamide activation and its hormonal control in vitro and in vivo. Int J Cancer 94 (2001) 733-742
228. Pyerin W., Horn F., and Taniguchi H. Posttranslational modifications of the cytochrome P-450 monooxygenase system. J Cancer Res Clin Oncol 113 (1987) 155-159
229. Pyerin W., and Taniguchi H. Phosphorylation of hepatic phenobarbital-inducible cytochrome P-450. EMBO J 8 (1989) 3003-3010
230. Bartlomowicz B., Friedberg T., Utesch D., Molitor E., Platt K., and Oesch F. Regio- and stereoselective regulation of monooxygenase activities by isoenzyme-selective phosphorylation of cytochrome P450. Biochem Biophys Res Commun 160 (1989) 46-52
231. Oesch-Bartlomowicz B., Padma P., Becker R., Richter B., Hengstler J., Freeman J., et al. Differential modulation of CYP2E1 activity by cAMP-dependent protein kinase upon Ser129 replacement. Exp Cell Res 242 (1998) 294-302
232. Oesch-Bartlomowicz B., Arens H., Richter B., Hengstler J., and Oesch F. Control of the mutagenicity of aromatic amines by protein kinases and phosphatases. I. The protein phosphatase inhibitors okadaic acid and ortho-vanadate drastically reduce the mutagenicity of aromatic amines. Arch Toxicol 71 (1997) 601-611
233. Oesch-Bartlomowicz B., Huelster A., Wiss O., Antoniou-Lipfert P., Dietrich C., Arand M., et al. Aryl hydrocarbon receptor activation by cAMP vs. dioxin: Divergent signaling pathways. Proc Natl Acad Sci USA 102 (2005) 9218-9223
234. Abdel-Razzak Z., Garlatti M., Aggerbeck M., and Barouki R. Determination of interleukin-4-responsive region in the human cytochrome P450 2E1 gene promoter. Biochem Pharmacol 68 (2004) 1371-1381
235. Abdel-Razzak Z., Loyer P., Fautrel A., Gautier J., Corcos L., Turlin B., et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44 (1993) 707-715
236. Morgan E. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29 (1997) 1129-1188
237. Muntane-Relat J., Ourlin J., Domergue J., and Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22 (1995) 1143-1153
238. Shedlofsky S., Israel B., Tosheva R., and Blouin R. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol 43 (1997) 627-632
239. Devchand P., Keller H., Peters J., Vazquez M., Gonzalez F., and Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
240. Renton K., and Nicholson T. Hepatic and central nervous system cytochrome P450 are down-regulated during lipopolysaccharide-evoked localized inflammation in brain. J Pharmacol Exp Ther 294 (2000) 524-530
241. Tindberg N., Ingelman-Sundberg M., Baldwin H., and Cross A. Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury. Mol Pharmacol 50 (1996) 1065-1072
242. Shimamoto Y., Kitamura H., Hoshi H., Kazusaka A., Funae Y., Imaoka S., et al. Differential alterations in levels of hepatic microsomal cytochrome P450 isozymes following intracerebroventricular injection of bacterial lipopolysaccharide in rats. Arch Toxicol 72 (1998) 492-498
243. Shimamoto Y., Kitamura H., Iwai M., Saito M., Kazusaka A., and Fujita S. Mechanism of decrease in levels of hepatic P450 isozymes induced by intracerebral endotoxin: Independence from sympathetic nervous and adrenocortical systems. Arch Toxicol 73 (1999) 41-49
244. Dai Y., Rashba-Step J., and Cederbaum A. Stable expression of human cytochrome P450 2E1 in HepG2 cells: Characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 32 (1993) 6928-6937
245. White R., and Coon M. Oxygen activation by cytochrome P-450. Annu Rev Biochem 49 (1980) 315-356
246. Park J., Shigenaga M., and Ames B. Induction of cytochrome P4501A1 by 2,3,7, 8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proc Natl Acad Sci USA 93 (1996) 2322-2327
247. Harbrecht B., Di Silvio M., Chough V., Kim Y., Simmons R., and Billiar T. Glutathione regulates nitric oxide synthase in cultured hepatocytes. Ann Surg 225 (1997) 76-87
248. El-Kadi A., Bleau A., Dumont I., Maurice H., and du Souich P. Role of reactive oxygen intermediates in the decrease of hepatic cytochrome P450 activity by serum of humans and rabbits with an acute inflammatory reaction. Drug Metab Dispos 28 (2000) 1112-1120
249. Campbell W. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci 21 (2000) 125-127
250. Fisslthaler B., Hinsch N., Chataigneau T., Popp R., Kiss L., Busse R., et al. Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 36 (2000) 270-275
251. Kessler P., Popp R., Busse R., and Schini-Kerth V. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 99 (1999) 1878-1884
252. Kozak W., Kluger M., Kozak A., Wachulec M., and Dokladny K. Role of cytochrome P-450 in endogenous antipyresis. Am J Physiol Regul Integr Comp Physiol 279 (2000) R455-R460
253. ω-hydroxyarginine to citrulline and nitrogen oxides and occurrence in no synthases of a sequence very similar to the heme-binding sequence in P450s. Biochem Biophys Res Commun 192 (1993) 53-60
254. Fantuzzi G., Galli G., Zinetti M., Fratelli M., and Ghezzi P. The upregulating effect of dexamethasone on tumor necrosis factor production is mediated by a nitric oxide-producing cytochrome P450. Cell Immunol 160 (1995) 305-308
255. Kuo P., Abe K., and Dafoe D. Cytochrome P450IIIA activity and cytokine-mediated synthesis of nitric oxide. Surgery 118 (1995) 310-317
256. Fantuzzi G., Cantoni L., Sironi M., and Ghezzi P. Inhibitors of cytochrome P450 suppress tumor necrosis factor production. Cell Immunol 150 (1993) 417-424
257. Carlson T., and Billings R. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450. Mol Pharmacol 49 (1996) 796-801
258. Khatsenko O., Boobis A., and Gross S. Evidence for nitric oxide participation in down-regulation of CYP2B1/2 gene expression at the pretranslational level. Toxicol Lett 90 (1997) 207-216
259. Roberts E., Lin H., Crowley J., Vuletich J., Osawa Y., and Hollenberg P. Peroxynitrite-mediated nitration of tyrosine and inactivation of the catalytic activity of cytochrome P450 2B1. Chem Res Toxicol 11 (1998) 1067-1074
260. Panesar N., Tolman K., and Mazuski J. Endotoxin stimulates hepatocyte interleukin-6 production. J Surg Res 85 (1999) 251-258
261. Sewer M., and Morgan E. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1beta and endotoxin in primary rat hepatocytes. Biochem Pharmacol 54 (1997) 729-737
262. Liu S., Khemlani L., Shapiro R., Johnson M., Liu K., Geller D., et al. Expression of CD14 by hepatocytes: Upregulation by cytokines during endotoxemia. Infect Immun 66 (1998) 5089-5098
263. Siewert E., Bort R., Kluge R., Heinrich P., Castell J., and Jover R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32 (2000) 49-55
264. Milosevic N., Schawalder H., and Maier P. Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes. Eur J Pharmacol 368 (1999) 75-87
265. Tinel M., Elkahwaji J., Robin M., Fardel N., Descatoire V., Haouzi D., et al. Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther 289 (1999) 649-655
266. Alam T., An M., and Papaconstantinou J. Differential expression of three C/EBP isoforms in multiple tissues during the acute phase response. J Biol Chem 267 (1992) 5021-5024
267. Jover R., Bort R., Gomez-Lechon M., and Castell J. Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett 431 (1998) 227-230
268. Postlind H., Vu T., Tukey R., and Quattrochi L. Response of human CYP1-luciferase plasmids to 2,3,7,8-tetrachlorodibenzo-p-dioxin and polycyclic aromatic hydrocarbons. Toxicol Appl Pharmacol 118 (1993) 255-262
269. Hodek P., Trefil P., and Stiborova M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 139 (2002) 1-21
270. Amakura Y., Tsutsumi T., Nakamura M., Kitagawa H., Fujino J., Sasaki K., et al. Activation of the aryl hydrocarbon receptor by some vegetable constituents determined using in vitro reporter gene assay. Biol Pharm Bull 26 (2003) 232-239
271. Amakura Y., Tsutsumi T., Nakamura M., Kitagawa H., Fujino J., Sasaki K., et al. Preliminary screening of the inhibitory effect of food extracts on activation of the aryl hydrocarbon receptor induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biol Pharm Bull 25 (2002) 272-274
272. Jeuken A., Keser B., Khan E., Brouwer A., Koeman J., and Denison M. Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits. J Agric Food Chem 51 (2003) 5478-5487
273. Ernst E. St John's Wort supplements endanger the success of organ transplantation. Arch Surg 137 (2002) 316-319
274. Fugh-Berman A. Herb-drug interactions. Lancet 355 (2000) 134-138
275. Fugh-Berman A. Herbal supplements: Indications, clinical concerns, and safety. Nutr Today 37 (2002) 122-124
276. Piscitelli S., Burstein A., Chaitt D., Alfaro R., and Falloon J. Indinavir concentrations and St John's wort. Lancet 355 (2000) 547-548
277. Moore L., Goodwin B., Jones S., Wisely G., Serabjit-Singh C., Willson T., et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97 (2000) 7500-7502
278. Wentworth J., Agostini M., Love J., Schwabe J., and Chatterjee V. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 166 (2000) R11-R16
279. Brigelius-Flohe R. Induction of drug metabolizing enzymes by vitamin E. J Plant Physiol 162 (2005) 797-802
280. Landes N., Pfluger P., Kluth D., Birringer M., Ruhl R., Bol G., et al. Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol 65 (2003) 269-273
281. Lilja J., Kivisto K., and Neuvonen P. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 66 (1999) 118-127
282. Lilja J., Kivisto K., and Neuvonen P. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 68 (2000) 384-390
283. Lilja J., Neuvonen M., and Neuvonen P. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58 (2004) 56-60
284. Bailey D., and Dresser G. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 4 (2004) 281-297
285. Barclay T., Peters J., Sewer M., Ferrari L., Gonzalez F., and Morgan E. Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. J Pharmacol Exp Ther 290 (1999) 1250-1257
286. Imaoka S., Terano Y., and Funae Y. Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation. Arch Biochem Biophys 278 (1990) 168-178
287. Mitchell S., Sewer M., Kardar S., and Morgan E. Characterization of CYP4A induction in rat liver by inflammatory stimuli: Dependence on sex, strain, and inflammation-evoked hypophagia. Drug Metab Dispos 29 (2001) 17-22
288. Sewer M., Barclay T., and Morgan E. Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene. Mol Pharmacol 54 (1998) 273-279
289. Ronis M., Huang J., Longo V., Tindberg N., Ingelman-Sundberg M., and Badger T. Expression and distribution of cytochrome P450 enzymes in male rat kidney: Effects of ethanol, acetone and dietary conditions. Biochem Pharmacol 55 (1998) 123-129
290. Chalasani N., Gorski J., Asghar M., Asghar A., Foresman B., Hall S., et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37 (2003) 544-550
291. Emery M., Fisher J., Chien J., Kharasch E., Dellinger E., Kowdley K., et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38 (2003) 428-435
292. Lucas D., Farez C., Bardou L., Vaisse J., Attali J., and Valensi P. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 12 (1998) 553-558
293. Wang Z., Hall S., Maya J., Li L., Asghar A., and Gorski J. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55 (2003) 77-85
294. Xu C., Li C., and Kong A. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28 (2005) 249-268
295. Coumoul X., Diry M., Robillot C., and Barouki R. Differential regulation of cytochrome P450 1A1 and 1B1 by a combination of dioxin and pesticides in the breast tumor cell line MCF-7. Cancer Res 61 (2001) 3942-3948
296. Wyde M., Bartolucci E., Ueda A., Zhang H., Yan B., Negishi M., et al. The environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor. Mol Pharmacol 64 (2003) 474-481
297. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb 10 (2003) 140-144
298. Tornio A., Pasanen M., Laitila J., Neuvonen P., and Backman J. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 97 (2005) 104-108
299. Nishio S., Watanabe H., Kosuge K., Uchida S., Hayashi H., and Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 28 (2005) 223-227
300. Andrus M. Oral anticoagulant drug interactions with statins: Case report of fluvastatin and review of the literature. Pharmacotherapy 24 (2004) 285-290
301. Barry M. Rosuvastatin-warfarin drug interaction. Lancet 363 (2004) 328
302. Stern R., Abel R., Gibson G., and Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 37 (1997) 1062-1064
303. Caro A., and Cederbaum A. Role of cytochrome P450 in phospholipase A2- and arachidonic acid-mediated cytotoxicity. Free Radic Biol Med 40 (2006) 364-375
304. + channels and contraction in mammalian heart cells. J Physiol 508 (1998) 777-792
305. Capdevila J., and Falck J. Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 68-69 (2002) 325-344
306. Capdevila J., Nakagawa K., and Holla V. The CYP P450 arachidonate monooxygenases: Enzymatic relays for the control of kidney function and blood pressure. Adv Exp Med Biol 525 (2003) 39-46
307. Powell P., Wolf I., and Lasker J. Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Arch Biochem Biophys 335 (1996) 219-226
308. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res 49 (2004) 525-533
309. Coon M. Omega oxygenases: Nonheme-iron enzymes and P450 cytochromes. Biochem Biophys Res Commun 338 (2005) 378-385
310. Yu Z., Xu F., Huse L., Morisseau C., Draper A., Newman J., et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87 (2000) 992-998
311. Campbell W., Gebremedhin D., Pratt P., and Harder D. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78 (1996) 415-423
312. + channel opening substance in monkey lingual artery. Br J Pharmacol 128 (1999) 802-808
313. Gross E., Nithipatikom K., Hsu A., Peart J., Falck J., Campbell W., et al. Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol 37 (2004) 1245-1249
314. + channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol 537 (2001) 811-827
315. Hoebel B., and Graier W. 11,12-Epoxyeicosatrienoic acid stimulates tyrosine kinase activity in porcine aortic endothelial cells. Eur J Pharmacol 346 (1998) 115-117
316. Spector A., Fang X., Snyder G., and Weintraub N. Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Prog Lipid Res 43 (2004) 55-90
317. Fukao M., Mason H., Kenyon J., Horowitz B., and Keef K. Regulation of BK(Ca) channels expressed in human embryonic kidney 293 cells by epoxyeicosatrienoic acid. Mol Pharmacol 59 (2001) 16-23
318. Jackson W. Potassium channels in the peripheral microcirculation. Microcirculation 12 (2005) 113-127
319. Campbell W., Holmes B., Falck J., Capdevila J., and Gauthier K. Regulation of potassium channels in coronary smooth muscle by adenoviral expression of cytochrome P-450 epoxygenase. Am J Physiol Heart Circ Physiol 290 (2006) H64-H71
320. Krotz F., Riexinger T., Buerkle M., Nithipatikom K., Gloe T., Sohn H., et al. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 24 (2004) 595-600
321. + channels and p42/p44 MAPK pathway. Circ Res 95 (2004) 506-514
322. Yang B., Graham L., Dikalov S., Mason R., Falck J., Liao J., et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 60 (2001) 310-320
323. Fleming I., Michaelis U., Bredenkotter D., Fisslthaler B., Dehghani F., Brandes R., et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88 (2001) 44-51
324. Michaelis U., Falck J., Schmidt R., Busse R., and Fleming I. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol 25 (2005) 321-326
325. Maier K., and Roman R. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens 10 (2001) 81-87
326. Oyekan A., McAward K., and McGiff J. Renal functional effects of endothelins: Dependency on cytochrome P450-derived arachidonate metabolites. Biol Res 31 (1998) 209-215
327. Oyekan A., and McGiff J. Functional response of the rat kidney to inhibition of nitric oxide synthesis: Role of cytochrome p450-derived arachidonate metabolites. Br J Pharmacol 125 (1998) 1065-1073
328. Croft K., McGiff J., Sanchez-Mendoza A., and Carroll M. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol 279 (2000) F544-F551
329. McGiff J., and Quilley J. 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens 10 (2001) 231-237
330. Imig J. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol 279 (2000) F965-F981
331. Amaral S., Maier K., Schippers D., Roman R., and Greene A. CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol 284 (2003) H1528-H1535
332. Kroetz D., and Xu F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol 45 (2005) 413-438
333. Sarkis A., and Roman R. Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Curr Drug Metab 5 (2004) 245-256
334. Harder D., Lange A., Gebremedhin D., Birks E., and Roman R. Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. J Vasc Res 34 (1997) 237-243
335. Ljubimov A., and Grant M. P450 in the angiogenesis affair: The unusual suspect. Am J Pathol 166 (2005) 341-344
336. Pratt P., Medhora M., and Harder D. Mechanisms regulating cerebral blood flow as therapeutic targets. Curr Opin Investig Drugs 5 (2004) 952-956
337. Sacerdoti D., Gatta A., and McGiff J. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 72 (2003) 51-71
338. Zhao X., and Imig J. Kidney CYP450 enzymes: Biological actions beyond drug metabolism. Curr Drug Metab 4 (2003) 73-84
339. Bondy S., and Naderi S. Contribution of hepatic cytochrome P450 systems to the generation of reactive oxygen species. Biochem Pharmacol 48 (1994) 155-159
340. Puntarulo S., and Cederbaum A. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic Biol Med 24 (1998) 1324-1330
341. Bylund J., Ericsson J., and Oliw E. Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. Anal Biochem 265 (1998) 55-68
342. Moran J., Mitchell L., Bradbury J., Qu W., Zeldin D., Schnellmann R., et al. Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic P450s. Toxicol Appl Pharmacol 168 (2000) 268-279
343. Hennig B., Meerarani P., Ramadass P., Watkins B., and Toborek M. Fatty acid-mediated activation of vascular endothelial cells. Metabolism 49 (2000) 1006-1013
344. Viswanathan S., Hammock B., Newman J., Meerarani P., Toborek M., and Hennig B. Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. J Am Coll Nutr 22 (2003) 502-510
345. Slim R., Hammock B., Toborek M., Robertson L., Newman J., Morisseau C., et al. The role of methyl-linoleic acid epoxide and diol metabolites in the amplified toxicity of linoleic acid and polychlorinated biphenyls to vascular endothelial cells. Toxicol Appl Pharmacol 171 (2001) 184-193
346. Toborek M., and Hennig B. The role of linoleic acid in endothelial cell gene expression. Relationship to atherosclerosis. Subcell Biochem 30 (1998) 415-436
347. Yu Z., Huse L., Adler P., Graham L., Ma J., Zeldin D., et al. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 57 (2000) 1011-1120
348. Frisbee J., Falck J., and Lombard J. Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. Am J Physiol Heart Circ Physiol 278 (2000) H1517-H1526
349. Kroetz D., Huse L., Thuresson A., and Grillo M. Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol Pharmacol 52 (1997) 362-372
350. Pomposiello S., Carroll M., Falck J., and McGiff J. Epoxyeicosatrienoic acid-mediated renal vasodilation to arachidonic acid is enhanced in SHR. Hypertension 37 (2001) 887-893
351. Moreno C., Maier K., Hoagland K., Yu M., and Roman R. Abnormal pressure-natriuresis in hypertension: Role of cytochrome P450 metabolites of arachidonic acid. Am J Hypertens 14 (2001) 90S-97S
352. Holla V., Makita K., Capdevila J., and Zaphiropoulos P. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Investig 104 (1999) 751-760
353. Liclican E., McGiff J., Pedraza P., Ferreri N., Falck J., and Carroll M. Exaggerated response to adenosine in kidneys from high salt-fed rats: Role of epoxyeicosatrienoic acids. Am J Physiol Renal Physiol 289 (2005) F386-F392
354. Taniguchi J., Honda H., Shibusawa Y., Iwata T., and Notoya Y. Alteration in endothelial function and modulation by treatment with pioglitazone in rabbit renal artery from short-term hypercholesterolemia. Vascul Pharmacol 43 (2005) 47-55
355. Katakam P., Hoenig M., Ujhelyi M., and Miller A. Cytochrome P450 activity and endothelial dysfunction in insulin resistance. J Vasc Res 37 (2000) 426-434
356. Huhtasaari F., Asplund K., Lundberg V., Stegmayr B., and Wester P. Tobacco and myocardial infarction: Is snuff less dangerous than cigarettes?. BMJ 305 (1992) 1252-1256
357. Huhtasaari F., Lundberg V., Eliasson M., Janlert U., and Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction: A population-based study in middle-aged men. J Am Coll Cardiol 34 (1999) 1784-1790
358. Jimenez-Ruiz C., Kunze M., and Fagerstrom K. Nicotine replacement: A new approach to reducing tobacco-related harm. Eur Respir J 11 (1998) 473-479
359. Holay M., Paunikar N., Joshi P., Sahasrabhojney V., and Tankhiwale S. Effect of passive smoking on endothelial function in: Healthy adults. J Assoc Physicians India 52 (2004) 114-117
360. Xu C., Pessah-Rasmussen H., and Stavenow L. Interactions between cultured bovine arterial endothelial and smooth muscle cells: Effects of injury on the release of growth stimulating and growth inhibiting substances. Pharmacol Toxicol 69 (1991) 195-200
361. Xu C., Stavenow L., and Pessah-Rasmussen H. Interactions between cultured bovine arterial endothelial and smooth muscle cells; effects of modulated low density lipoproteins on cell proliferation and prostacyclin release. Scand J Clin Lab Invest 54 (1994) 191-198
362. Zhang J., Cao Y., Xu C., and Edvinsson L. Lipid-soluble smoke particles damage endothelial cells and reduce endothelium-dependent dilatation in rat and man. BMC Cardiovasc Disord 6 (2006) 3
363. Cirillo P., De Rosa S., Pacileo M., Gargiulo A., Leonardi A., Angri V., et al. Nicotine induces tissue factor expression in cultured endothelial and smooth muscle cells. J Thromb Haemost 4 (2006) 453-458
364. Botto N., Rizza A., Colombo M., Mazzone A., Manfredi S., Masetti S., et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 493 (2001) 23-30
365. Penn A. Role of somatic mutation in atherosclerosis. Prog Clin Biol Res 340C (1990) 93-100
366. Ross J., Stagliano N., Donovan M., Breitbart R., and Ginsburg G. Atherosclerosis: A cancer of the blood vessels?. Am J Clin Pathol 116 Suppl. (2001) S97-S107
367. Benditt E. Implications of the monoclonal character of human atherosclerotic plaques. Beitr Pathol 158 (1976) 405-416
368. Benditt E., and Benditt J. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 70 (1973) 1753-1756
369. Hao H., Gabbiani G., and Bochaton-Piallat M. Arterial smooth muscle cell heterogeneity: Implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 23 (2003) 1510-1520
370. Murry C., Gipaya C., Bartosek T., Benditt E., and Schwartz S. Monoclonality of smooth muscle cells in human atherosclerosis. Am J Pathol 151 (1997) 697-705
371. Albert R., Vanderlaan M., Burns F., and Nishizumi M. Effect of carcinogens on chicken atherosclerosis. Cancer Res 37 (1977) 2232-2235
372. Penn A., and Snyder C. Arteriosclerotic plaque development is 'promoted' by polynuclear aromatic hydrocarbons. Carcinogenesis 9 (1988) 2185-2189
373. Randerath E., Mittal D., and Randerath K. Tissue distribution of covalent DNA damage in mice treated dermally with cigarette 'tar': Preference for lung and heart DNA. Carcinogenesis 9 (1988) 75-80
374. Randerath E., Miller R., Mittal D., Avitts T., Dunsford H., and Randerath K. Covalent DNA damage in tissues of cigarette smokers as determined by 32P-postlabeling assay. J Natl Cancer Inst 81 (1989) 341-347
375. Van Schooten F., Hirvonen A., Maas L., De Mol B., Kleinjans J., Bell D., et al. Putative susceptibility markers of coronary artery disease: Association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB J 12 (1998) 1409-1417
376. Zhang Y., Weksler B., Wang L., Schwartz J., and Santella R. Immunohistochemical detection of polycyclic aromatic hydrocarbon-DNA damage in human blood vessels of smokers and non-smokers. Atherosclerosis 140 (1998) 325-331
377. Izzotti A., De Flora S., Petrilli G., Gallagher J., Rojas M., Alexandrov K., et al. Cancer biomarkers in human atherosclerotic lesions: Detection of DNA adducts. Cancer Epidemiol Biomarkers Prev 4 (1995) 105-110
378. Zhao W., Parrish A., and Ramos K. Constitutive and inducible expression of cytochrome P450IA1 and P450IB1 in human vascular endothelial and smooth muscle cells. In Vitro Cell Dev Biol Anim 34 (1998) 671-673
379. Hammons G., Milton D., Stepps K., Guengerich F., Tukey R., and Kadlubar F. Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis 18 (1997) 851-854
380. Shou M., Gonzalez F., and Gelboin H. Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase. Biochemistry 35 (1996) 15807-15813
381. Turesky R., Constable A., Richoz J., Varga N., Markovic J., Martin M., et al. Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P450 1A2. Chem Res Toxicol 11 (1998) 925-936
382. Landi M., Bertazzi P., Shields P., Clark G., Lucier G., Garte S., et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4 (1994) 242-246
383. Sachse C., Brockmoller J., Bauer S., and Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47 (1999) 445-449
384. Wang X., Greco M., Sim A., Duarte N., Wang J., and Wilcken D. Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 162 (2002) 391-397
385. Shertzer H., Clay C., Genter M., Schneider S., Nebert D., and Dalton T. Cyp1a2 protects against reactive oxygen production in mouse liver microsomes. Free Radic Biol Med 36 (2004) 605-617
386. Smith A., Davies R., Dalton T., Miller M., Judah D., Riley J., et al. Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics 111 (2003) 45-51
387. Frye R., Schneider V., Frye C., and Feldman A. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 8 (2002) 315-319
388. Cornelis M., El-Sohemy A., and Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 41 (2004) 758-762
389. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29 (2001) 91-95
390. Murray M. Altered CYP expression and function in response to dietary factors: Potential roles in disease pathogenesis. Curr Drug Metab 7 (2006) 67-81
391. Barnett C., Rudd S., Flatt P., and Ioannides C. Sex differences in the diabetes-induced modulation of rat hepatic cytochrome P450 proteins. Biochem Pharmacol 45 (1993) 313-319
392. Bellward G., Chang T., Rodrigues B., McNeill J., Maines S., Ryan D., et al. Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat. Mol Pharmacol 33 (1988) 140-143
393. Dong Z., Hong J., Ma Q., Li D., Bullock J., Gonzalez F., et al. Mechanism of induction of cytochrome P-450(ac) (P-450(j)) in chemically induced and spontaneously diabetic rats. Arch Biochem Biophys 263 (1988) 29-35
394. Yamazoe Y., Murayama N., Shimada M., Yamauchi K., and Kato R. Cytochrome P450 in livers of diabetic rats: Regulation by growth hormone and insulin. Arch Biochem Biophys 268 (1989) 567-575
395. Hong J., Pan J., and Gonzalez F. The induction of a specific form of cytochrome P-450 (P-450j) by fasting. Biochem Biophys Res Commun 142 (1987) 1077-1083
396. Johansson I., Ekstrom G., Scholte B., Puzycki D., Jornvall H., and Ingelman-Sundberg M. Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: Regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies. Biochemistry 27 (1988) 1925-1934
397. Johansson I., Lindros K., Eriksson H., and Ingelman-Sundberg M. Transcriptional control of CYP2E1 in the previous liver region and during starvation. Biochem and Biophys Res Commun 173 (1990) 331-338
398. Raucy J., Lasker J., Kraner J., Salazar D., Lieber C., and Corcoran G. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 39 (1991) 275-280
399. Yun Y., Casazza J., Sohn D., Veech R., and Song B. Pretranslational activation of cytochrome P450IIE during ketosis induced by a high fat diet. Mol Pharmacol 41 (1992) 474-479
400. Grundy S., Cleeman J., Merz C., Brewer Jr. H., Clark L., Hunninghake D., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
401. Flockhart D., and Tanus-Santos J. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 162 (2002) 405-412
402. Schmitz G., and Langmann T. Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol 44 (2006) 75-89
403. Paumelle R., Blanquart C., Briand O., Barbier O., Duhem C., Woerly G., et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98 (2006) 361-369
404. Libby P., and Aikawa M. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 8 (2002) 1257-1262
405. Nakai D., Nakagomi R., Furuta Y., Tokui T., Ikeda T., Nishimura K., et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297 (2001) 861-867
406. Beaird S. HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash DC: 1996). 40 (2000) 637-644
407. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 (1999) 413-428
408. Stein E. New statins and new doses of older statins. Curr Atheroscler Rep 3 (2001) 14-18
409. Ucar M., Mjörndal T., and Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22 (2000) 441-457
410. Bellosta S., Paoletti R., and Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 109 (2004) III50-III57
411. Scripture C., and Pieper J. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 40 (2001) 263-281
412. Paoletti R., Corsini A., and Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 3 (2002) 35-40
413. Kajinami K., Brousseau M., Ordovas J., and Schaefer E. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 93 (2004) 104-107
414. Kivisto K., Niemi M., Schaeffeler E., Pitkala K., Tilvis R., Fromm M., et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14 (2004) 523-525
415. Ishikawa C., Anjo S., Ozaki H., Shirai K., Nakajima T., Inoue I., et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 49 (2004) 582-585
416. Mulder A., Van Lijf H., Bon M., Van den Bergh F., Touw D., Neef C., et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 70 (2001) 546-551
417. Kirchheiner J., Kudlicz D., Meisel C., Bauer S., Meineke I., Roots I., et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 74 (2003) 186-194
418. Pullinger C., Eng C., Salen G., Shefer S., Batta A., Erickson S., et al. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 110 (2002) 109-117
419. Wang J., Freeman D., Grundy S., Cohen J., Guerra R., and Levine D. Linkage between cholesterol 7α-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J Clin Invest 101 (1998) 1283-1291
420. Kajinami K., Brousseau M., Ordovas J., and Schaefer E. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 175 (2004) 287-293
421. Barbier O., Pineda Torra I., Duguay Y., Blanquart C., Fruchart J., Glineur C., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22 (2002) 717-726
422. Zambon A., Gervois P., Pauletto P., Fruchart J., and Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-{alpha} activators. Clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26 (2006) 977-986
423. Chinetti-Gbaguidi G., Fruchart J., and Staels B. Pleiotropic effects of fibrates. Curr Atheroscler Rep 7 (2005) 396-401
424. Staels B., and Fruchart J. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
425. Ye H., and Zhao S. Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects. Med Hypotheses 66 (2006) 495-500
426. Chinetti-Gbaguidi G., Fruchart J., and Staels B. Therapeutical effects of PPAR agonists assessed by biomarker modulation. Biomarkers 10 Suppl. 1 (2005) S30-S36
427. Steiner G. A new perspective in the treatment of dyslipidemia: Can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?. Treat Endocrinol 4 (2005) 311-317
428. Betteridge D. Lipid-lowering trials in diabetes. Curr Opin Lipidol 12 (2001) 619-623
429. Rubins H. Triglycerides and coronary heart disease: Implications of recent clinical trials. J Cardiovasc Risk 7 (2000) 339-345
430. Calkin A., Cooper M., Jandeleit-Dahm K., and Allen T. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49 (2006) 766-774
431. Delerive P., Gervois P., Fruchart J., and Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275 (2000) 36703-36707
432. Tharappel J., Nalca A., Owens A., Ghabrial L., Konz E., Glauert H., et al. Cell proliferation and apoptosis are altered in mice deficient in the NF-kappaB p50 subunit after treatment with the peroxisome proliferator ciprofibrate. Toxicol Sci 75 (2003) 300-308
433. Xu X., Otsuki M., Saito H., Sumitani S., Yamamoto H., Asanuma N., et al. PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology 142 (2001) 3332-3339
434. Kleemann R., Gervois P., Verschuren L., Staels B., Princen H., and Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101 (2003) 545-551
435. Coban E., Ozdogan M., Yazicioglu G., and Sari R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients. Int J Clin Pract 59 (2005) 415-418
436. Wang T., Chen W., Lin J., Cheng C., Chen M., and Lee Y. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: Relations with baseline lipid profiles. Atherosclerosis 170 (2003) 315-323
437. Nilakantan V., Spear B., and Glauert H. Liver-specific catalase expression in transgenic mice inhibits NF-kappaB activation and DNA synthesis induced by the peroxisome proliferator ciprofibrate. Carcinogenesis 19 (1998) 631-637
438. Poynter M., and Daynes R. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273 (1998) 32833-32841
439. Miller D., and Spence J. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34 (1998) 155-162
440. Kyrklund C., Backman J., Neuvonen M., and Neuvonen P. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73 (2003) 538-544
441. Shitara Y., Hirano M., Sato H., and Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311 (2004) 228-236
442. Ogilvie B., Zhang D., Li W., Rodrigues A., Gipson A., Holsapple J., et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab Dispos 34 (2006) 191-197
443. Prueksaritanont T., Richards K., Qiu Y., Strong-Basalyga K., Miller A., Li C., et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 22 (2005) 71-78
444. Wang J., Neuvonen M., Wen X., Backman J., and Neuvonen P. Gemfibrozil inhibits CYP2c8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30 (2002) 1352-1356
445. Backman J., Kyrklund C., Kivisto K., Wang J., and Neuvonen P. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68 (2000) 122-129
446. Backman J., Kyrklund C., Neuvonen M., and Neuvonen P. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72 (2002) 685-691
447. Lilja J., Backman J., and Neuvonen P. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol 59 (2005) 433-439
448. Hajjar I., and Kotchen T. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
449. Kearney P., Whelton M., Reynolds K., Muntner P., Whelton P., and He J. Global burden of hypertension: Analysis of worldwide data. Lancet 365 (2005) 217-223
450. Braunwald E., Antman E., Beasley J., Califf R., Cheitlin M., Hochman J., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002-summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106 (2002) 1893-1900
451. Chobanian A., Bakris G., Black H., Cushman W., Green L., Izzo Jr. J., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
452. Materson B. Variability in response to antihypertensive drug treatment. Hypertension 43 (2004) 1166-1167
453. Regardh C., and Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5 (1980) 557-569
454. van der Does R., Hauf-Zachariou U., Pfarr E., Holtbrugge W., Konig S., Griffiths M., et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol 83 (1999) 643-649
455. Arnett D., Claas S., and Glasser S. Pharmacogenetics of antihypertensive treatment. Vasc Pharmacol 44 (2006) 107-118
456. Zineh I., Beitelshees A., Gaedigk A., Walker J., Pauly D., Eberst K., et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76 (2004) 536-544
457. Fux R., Morike K., Prohmer A., Delabar U., Schwab M., Schaeffeler E., et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study. Clin Pharmacol Ther 78 (2005) 378-387
458. Nozawa T., Taguchi M., Tahara K., Hashimoto Y., Igarashi N., Nonomura M., et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: A comparison with bisoprolol. J Cardiovasc Pharmacol 46 (2005) 713-720
459. Hallberg P., Karlsson J., Kurland L., Lind L., Kahan T., Malmqvist K., et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypers 20 (2002) 2089-2093
460. Taavitsainen P., Kiukaanniemi K., and Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 56 (2000) 135-140
461. Bourriè M., Meunier V., Berger Y., and Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 27 (1999) 288-296
462. Yasar U., Tybring G., Hidestrand M., Oscarson M., Ingelman-Sundberg M., Dahl M., et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29 (2001) 1051-1056
463. Sanderson S., Emery J., and Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet? Systematic review and meta-analysis. Genet Med 7 (2005) 97-104
464. Visser L., Hofman A., van Duijn C., Stricker B., Vulto A., van Schaik R., et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 92 (2004) 61-66
465. Hummers-Pradier E., Hess S., Kochen M., Adham I., Papke T., and Pieske B. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 59 (2003) 213-219
466. Schalekamp T., Oosterhof M., Van Meegen E., Van Der Meer F., Conemans J., Hermans M., et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 76 (2004) 409-417
467. Kirchheiner J., Roots I., Goldammer M., Rosenkranz B., Brockmöller J., et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: Clinical relevance. Clin Pharmacokinet 44 (2005) 1209-1225
468. Holstein A., Plaschke A., Ptak M., Egberts E., El-Din J., Brockmöller J., et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol (2005) 60:103-106
469. Baldwin S., Clarke S., and Chenery R. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48 (1999) 424-432
470. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl Suppl. 121 (2001) 19-25
471. Scheen A. Hepatotoxicity with thiazolidinediones: Is it a class effect?. Drug Saf 24 (2001) 873-888
472. Yamazaki H., Shibata A., Suzuki M., Nakajima M., Yokoi T., Shimada N., et al. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27 (1999) 1260-1266